Michael MD - Biocept Chief VP
Insider
Michael MD is Chief VP of Biocept
| Age | 61 |
| Phone | 858 320 8200 |
| Web | https://biocept.com |
Biocept Management Efficiency
The company has return on total asset (ROA) of (0.5165) % which means that it has lost $0.5165 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8694) %, meaning that it created substantial loss on money invested by shareholders. Biocept's management efficiency ratios could be used to measure how well Biocept manages its routine affairs as well as how well it operates its assets and liabilities.Biocept currently holds 12.11 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Biocept has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biocept's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MS | Actinium Pharmaceuticals | 58 | |
| Melissa Berquist | iBio, Common Stock | N/A | |
| Nick DeLong | iBio, Common Stock | N/A | |
| Dr MS | Actinium Pharmaceuticals | N/A | |
| Thomas III | iBio, Common Stock | 57 | |
| Randy Maddux | iBio, Common Stock | 63 | |
| Greg Pyszczymuka | Aytu BioScience | 45 | |
| Dr DVM | iBio, Common Stock | 55 | |
| Stephen Kilmer | iBio, Common Stock | N/A | |
| Topher Brooke | Aytu BioScience | N/A | |
| Arun Swaminathan | Actinium Pharmaceuticals | N/A | |
| Christopher Brooke | Aytu BioScience | N/A | |
| Avinash MD | Actinium Pharmaceuticals | N/A | |
| Mike Jenkins | iBio, Common Stock | N/A | |
| Qing Liang | Actinium Pharmaceuticals | N/A | |
| Lisa Middlebrook | iBio, Common Stock | N/A | |
| Robert Lutz | iBio, Common Stock | 55 | |
Management Performance
| Return On Equity | -1.87 | |||
| Return On Asset | -0.52 |
Biocept Leadership Team
Elected by the shareholders, the Biocept's board of directors comprises two types of representatives: Biocept inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biocept. The board's role is to monitor Biocept's management team and ensure that shareholders' interests are well served. Biocept's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biocept's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Terry, Senior Vice President - Commercial Operations | ||
| Pavel Tsinberg, Director Devel | ||
| Soon Hahn, Founder | ||
| MBA RPh, VP Communications | ||
| Samuel Riccitelli, CEO Pres | ||
| Michael MD, Chief VP | ||
| Antonio Paternostro, VP Sales | ||
| Philippe Marchand, Chief Officer | ||
| Antonino Morales, Interim Director | ||
| Darrell Esq, Chief VP |
Biocept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biocept a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.87 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (10.38) % | |||
| Current Valuation | 5.92 M | |||
| Shares Outstanding | 2.63 M | |||
| Shares Owned By Insiders | 9.20 % | |||
| Shares Owned By Institutions | 1.98 % | |||
| Number Of Shares Shorted | 29.73 K | |||
| Price To Earning | 5.34 X | |||
| Price To Book | 0.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Biocept Stock
If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |